返回 Agendas
Session 6C: Clinical Track: Oncology and Pulmonary
Session Chair(s)
Arthur M. Krieg, MD
CEO and CSO
Checkmate Pharmaceuticals, United States
This session will present systemic oligonucleotide-based approaches to the treatment of cancer and inhaled delivery of oligonucleotides for asthma immunotherapy. The mechanisms to be discussed will include antisense and immune modulation, including both activation and inhibition of Toll-like receptor 9.
Speaker(s)
Synthetic Oligonucleotide-Based Antagonist of Endosomal TLRs: Preclinical and Clinical Proof-of-Concept
Sudhir Agrawal, PHD
Idera Pharmaceuticals, United States
President of Research
Dynavax/AZ Experience: Inhaled Oligos for Asthma
Sam Jackson, MD, MBA
Dynavax Technologies, United States
Executive Director, Clinical Development & Drug Safety
Preclinical and clinical studies with STAT3 ASOs
Paul Lyne, PHD
AstraZeneca, United States
Senior Project Director, Oncology iMed
Panel Discussion
All Session Speakers, United States